Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Dept of Interior
---Dept of Energy
---Dept of Transportation
---FDA
---USDA

Avian Flu
---USDA - APHIS - Foreign Animal Disease

Efforts to expand the Bio Economy & Bio Manufacturing
---Farm to Fly Act

Farm Bill
---Farm Bill Reauthorization

Food & Ag National Security
---China Biotechnology Regulations

Genetically Engineered (GE) Animals
---Efficient Science-Based Review of Biotech Products, FDA Approvals, Guidance, & Regulations

Genetically Engineered (GE) Plants
---EPA proposed revisions to regulations related to the oversight of certain plant-incorporated protectants (PIPs)

United States-Mexico-Canada Agreement (USMCA)
---USMCA Review

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), U.S. SENATE, White House Office, Health & Human Services - Dept of (HHS), Securities & Exchange Commission (SEC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

Avian Flu
---USDA - APHIS - Foreign Animal Disease

Farm Bill
---Farm Bill Reauthorization

Genetically Engineered (GE) Animals
---Efficient Science-Based Review of Biotech Products, FDA Approvals, Guidance, & Regulations

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---ASPR
---Centers for Disease Control and Prevention
---Department of Energy
---Department of Transportation
---EPA - Office of Biopesticides and Pollution Prevention Division
---FDA
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy
---National Institute of Health
---USDA

FY 2026 Appropriations for Specific Issues
--- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development, and Procurement
---Biofuels, Biomass Crop Assistance, and Biorefineries
---Biotechnology and Agriculture Trade Program
---Environment and Energy R&D
---Farm Bill Programs Energy Title IX
---Funding for Strategic National Stockpile
---Implementation of the Inflation Reduction Act
---NextGen Aircraft Technology - Fuels & Metrics
---Pandemic Preparedness
---Project Bio Shield
---Reauthorization of PAHPA
---Renewable Materials/BIO-based Products
---Vaccine Access & Compensation

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Implementation of the Inflation Reduction Act of 2022
---Renewable Chemicals/Bio-based Products



Renewable Chemicals/Bio-based Products
---Biomanufacturing and Jobs Act
---Investment Tax Credit

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Economic Council (NEC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation
---Oversight Pharmacy Benefit Managers

Artificial Intelligence (AI)

Bayh-Dole Act/Tech Transfer
---Bayh-Dole Act
---March-In Rights

Compulsory Licensing

Data Privacy
---A bill to prohibit contracting with certain biotechnology providers, and for other purposes
---American Privacy Rights Act
---Bio COMPETES (Draft)
---BIOSECURE Act
---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern
---House GOP RFI on Supply Chain

Diversity in Patenting
--- Inventor Diversity for Economic Advancement (IDEA) Act

Drug Patenting
---A bill to address patent thickets
---A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents
---Affordable Prescriptions for Patients Act
---FTC Orange Book Delisting Initiative
---Interagency Patent Coordination and Improvement Act of 2025
---Medication Affordability and Patient Integrity Act
---Orange Book Listing
---Prescription Pricing for the People Act
---Preserve Access to Affordable Generics and Biosimilars Act
---PTO Proposed Rules on Terminal Disclaimer Practice
---Restrictions on Intellectual Property Rights
---Stop STALLING Act
---Executive Order 14273: Lowering Drug Prices by Once Again Putting Americans First
---ETHIC Act

Foreign Drug Data Protection Law
---Bio COMPETES (Draft)
---BIOSECURE Act
---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern
---House GOP RFI on Supply Chain

Intellectual Property Enforcement
---China

Patent Reform
---Interagency Patent Coordination and Improvement Act
---Patent Eligibility Restoration Act (PERA)
---Patent Litigation Reform
---Prohibiting Adversarial Patents Act (PAPA)
---Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act

Patenting of Biological Inventions
---Patent Eligibility Restoration Act (PERA)
---Section 101 Modernization

World Health Organization (WHO)
---WHO Pandemic Preparedness Accord

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), Commerce - Dept of (DOC), Federal Trade Commission (FTC), Justice - Dept of (DOJ)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Agricultural Biorefinery Innovation and Opportunity Act
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
---AMMTO
---BETA
---Biofuels and SAF
---Biofuels, Biomass Crop Assistance, and Biorefineries
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Incentives for Sustainable Aviation Fuels

Biofuels and SAF
---Farm to Fly Act
---Incentives for Sustainable Aviation Fuels
---IRA Tax Credits
---Sustainable Aviation Fuels Tax Credit

Biomass Programs
---Climate Issues & impact on the agriculture, food, and forestry sectors

Biorefineries
---Agricultural Biorefinery Innovation and Opportunity
---Climate Issues & impact on the agriculture and food sectors

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

Efforts to expand the Bio Economy & Bio Manufacturing
---Farm to Fly Act

Farm Bill
---Farm Bill Reauthorization

Food & Ag National Security
---China Biotechnology Regulations

Genetically Engineered (GE) Animals
---Efficient Science-Based Review of Biotech Products, FDA Approvals, Guidance, & Regulations

Genetically Engineered (GE) Plants
---EPA proposed revisions to regulations related to the oversight of certain plant-incorporated protectants (PIPs)

Issues Relating to Medical Research and Animal Testing Models

United States-Mexico-Canada Agreement (USMCA)
---USMCA Review

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), U.S. Trade Representative (USTR), White House Office, Securities & Exchange Commission (SEC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FUE

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Agricultural Biorefinery Innovation and Opportunity Act
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
---AMMTO
---BETA
---Biofuels and SAF
---Biofuels, Biomass Crop Assistance, and Biorefineries
---Climate Change
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Incentives for Sustainable Aviation Fuels

Biofuels and SAF
---Farm to Fly Act
---Incentives for Sustainable Aviation Fuels
---IRA Tax Credits
---Sustainable Aviation Fuels Tax Credit

Biomass Programs
---Climate Issues & impact on the agriculture and food sectors

Biorefineries
---Agricultural Biorefinery Innovation and Opportunity Act
---Climate Issues & impact on the agriculture and food sectors

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---ASPR
---Centers for Disease Control and Prevention
---FDA
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy
---National Institute of Health
---BARDA

FY 2026 Appropriations for Specific Issues
--- Alternative Funding Programs
--- Antimicrobial Resistance (General)
--- Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--- CICP
--- Creating Hope Reauthorization Act
--- Drug Pricing
--- Funding for Strategic National Stockpile
--- Funding for Women's Health Research
--- Implementation of the Inflation Reduction Act (IRA)
--- Influenza Planning & Response
--- MCM PRV Reauthorization
--- Pandemic Preparedness - R&D Funding for Medical Countermeasures
--- PPRV
--- Prescription Drug User Fee Act (PDUFA) VII Implementation
--- Project Bioshield
--- Reauthorization of PAHPA
--- Vaccines and Infectious Diseases
--- Vaccine Injury Compensation Program
--- Section 317 Immunization Program

340B Drug Discount Program
--- 340B Accountability Act
---Executive Order on Access to Affordable Life-Saving Medications
---Program Implementation & Oversight
---PROTECT 340B Act
---SUSTAIN 340B Act

Accelerated Approval

Access to non-human Primates (NHPs)

Artificial Intelligence (AI)

Alternative Funding Programs

Biodefense Research, Development and Procurement Issues
---Bio COMPETES (Draft)
---Biodefense
---BIOSECURE Act
---Disease X Act
---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act)
---House GOP RFI on Supply Chain
---Implementation of Medical Countermeasure Innovation Act
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act
---Improving Data Accessibility Through Advancements (DATA) in Public Health Act
---MCM PRV Program Reauthorization
--- NDAA
--- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
--- Risky Research Review Act
--- Tropical Disease Priority Review Voucher (PRV) Program
--- VICP Loopholes
--- WHO Pandemic Preparedness Accord

Biosimilars
---Bio COMPETES (Draft)
---Biosimilar Copay
---Biosimilar Red Tape Elimination Act
---House GOP RFI on Supply Chain
---Interchangeability and Pharmacy Substitution
---Preserve Access to Affordable Generics and Biosimilars Act
---Reimbursement

Cell & Gene Therapy
--- H.R.1672 Maintaining Investments and New Innovation (MINI) Act

Climate Change

Data Privacy
---American Privacy Rights Act
---Bio COMPETES (Draft)
---BIOSECURE Act
---Clinical Trial Data in China
---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern
---House GOP RFI on Data Privacy

Diversity & Inclusion
---Decentralized Clinical Trials
---Implementation of Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act

Drug Evaluation and Review
---COVID-19 Lessons Learned
---FDA Hiring Flexibility
---Promising Pathway Act
---PDUFA
---FDA Reform

Drug Importation

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Drug Shortages
---Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
---Supply Chain Integrity and Traceability
---Compounding & Counterfeit Medicines

Drug Patenting
---A bill to address patent thickets
---Affordable Prescriptions for Patients Act
---Interagency Patent Coordination and Improvement Act
---Medication Affordability and Patient Integrity Act
---Patent Thickets
---Prescription Pricing for the People Act
---Preserve Access to Affordable Generics and Biosimilars Act
---Restrictions on Intellectual Property Rights
---Stop STALLING Act

Drug Pricing
---H.R.946: ORPHAN Cures Act
---H.R. 1492 Ensuring Pathways to Innovative Cures (EPIC) Act
--- H.R.1672 Maintaining Investments and New Innovation (MINI) Act
--- S.2082 Stronger Patents Act
--- Access to Innovative Treatments Act
--- Affordable Prescriptions for Patients Act
--- Biosimilar Red Tape Elimination Act
--- CMMI Authority
--- COVID-19 Pricing-Related Provisions
--- DRUG Act
--- Ensuring Timely Access to Generics
--- Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
--- Implementation of the Inflation Reduction Act (IRA)
--- Increasing Transparency in Generic Drug Application
--- Interagency Patent Coordination and Improvement Act
--- Lowering Drug Costs for American Families Act
--- Mandating Exclusive Review of Individual Treatments (MERIT) Act
--- Medicare Drug Price Negotiation Act
--- Medicare Negotiation and Competitive Licensing Act
--- Modernizing and Ensuring PBM Accountability (MEPA) Act
--- Most Favored Nation
--- National Coverage Determination
--- Patient Cost-Sharing and Implementation
--- PBM Reform
--- Pharmacy Benefit Manager Transparency Act
--- Prescription Drug Price Relief Act
--- Prescription Pricing for the People Act
--- Preserve Access to Affordable Generics and Biosimilars Act
--- Protecting Patient Access to Cancer and Therapies
--- Stop STALLING Act
--- Strengthening Innovation in Medicare and Medicaid Act

Efforts to expand the Bio Economy & Bio Manufacturing

Foreign Drug Data Protection Laws
---Bio COMPETES (Draft)
---BIOSECURE Act
---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern
---House GOP RFI on Supply Chain

Generic Drug Entry
--- Stop STALLING Act

Issues Relating to Medical Research and Animal Testing
---FDA Modernization Act 3.0

Medicaid
---Alternative Payment Arrangements for Gene Therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
--- Modernizing and Ensuring PBM Accountability (MEPA) Act
---Pharmacy Benefit Manager Transparency Act of 2025
---Pricing and Rebates
--- The Medicaid VBPs for Patients (MVP) Act
---Value-Based Purchasing (VBP) Rule

National Defense
---National Defense Authorization Act of 2025

National Security
---American Privacy Rights Act
---BIOSECURE Act
---Clinical Trial Data in China
--- Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern

Opioid Crisis
---Coverage and Reimbursement
---Non-Opioid Analgesics
---SUPPORT Act

Orphan Drug Issues
---H.R.946: ORPHAN Cures Act
---H.R.1262: Give Kids a Chance Act
---S. 946 ORPHAN Cures Act
---Finding Orphan-Disease Remedies with Antifungal Research and Development (FORWARD) Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Innovation in Pediatric Drugs Act of 2023
---Pediatric Priority Review Voucher Program
---Orphan Drug Tax Credit
---Retaining Access and Restoring Exclusivity (RARE) Act
---Rare Disease Pilot Program

Pandemic Preparedness
---Drug Supply Chain Management
---House GOP RFI on Supply Chain
--- Implementation of the Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act
---Medical Countermeasures PRV Reauthorization
---Monoclonal Antibody Coverage and Utilization
---Project Bio Shield
---Supply Chain Issues
---Temporarily Refundable R&D Credit
---TRIPS Waiver
---WHO Pandemic Preparedness Accord

Precision Medicine Initiative

Reimbursement and Coverage of Innovative Products
--- HR 3375 Fair Prescription Drug Prices for Americans Act
--- HR 3493 Global Fairness in Drug Pricing Act
--- S.1587 Fair Prescription Drug Prices for Americans Act
--- S.1818 Prescription Drug Price Relief Act
---CMMI Authority
--- End Price Gauging for Medications Act
---HELP Copays Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---In-Home Administration of Part B Drugs
---Lower Costs, More Cures Act
---Lower Costs, More Transparency Act
---Lowering Drug Costs for American Families Act
--- Mandating Exclusive Review of Individual Treatments (MERIT) Act
--- Medicare Drug Price Negotiation Act
---Medicare Part B Physician-Administered Products
---National Coverage Determination
---Patient Cost-Sharing and Smoothing
--- Prescription Drug Price Relief Act
---Protected Classes
--- SAFE STEP Act
--- SMART Prices Act
--- Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations
--- The Medicaid VBPs for Patients (MVP) Act
---Value-based Contracting and Communications
--- Value-Based Purchasing (VBP) Rule

Vaccines and Infectious Diseases
--- Access to Innovative Treatments Act
---Adult Immunization
--- Antimicrobial Resistance (General)
---CICP - General
--- Countermeasure Injury Compensation Fund Amendment Act
--- Finding Orphan-Disease Remedies with Antifungal Research and Development (FORWARD) Act
--- Let Injured Americans Be Legally Empowered (LIABLE) Act
--- Maternal Immunization
---MCM Manufacturing & Capacity
--- MCM R&D Incentives
--- Monoclonal Antibody Coverage and Utilization
--- National Coverage Determination
--- SAFE STEP Act
--- Vaccine Access Improvement Act
--- Vaccine and Antimicrobial Resistance Product Development and Incentives
--- Vaccine Injury Compensation Modernization Act
--- Vaccine Injury Compensation Program
--- Vaccine Quality Measure
--- Vaccine Safety
--- Vaccine Safety Net and Vaccine Infrastructure
--- Value of Vaccines and Vaccine Confidence
--- VICP CICP (Discussion Draft)
---HR 3701 Family Vaccine Protection Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Treasury - Dept of, White House Office, Patent & Trademark Office (PTO), Natl Security Council (NSC), U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---ASPR
---BARDA
--- Centers for Disease Control and Prevention Vaccine Programs
--- Health Resources and Services Administration (HRSA)
--- HHS Office of Infectious Disease and HIV/AIDS Policy
--- National Institute of Health
--- BARDA
--- ASPR

FY 2026 Appropriations for Specific Issues
--- Antimicrobial Resistance (General)
--- Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--- Funding for Strategic National Stockpile
--- MCM PRV Reauthorization
--- Reauthorization of PAHPA
--- VICP
--- Prescription Drug User Fee Act (PDUFA) VII Implementation
--- Funding for Women's Health Research
--- Pandemic Flu
--- Pandemic Preparedness - R&D Funding for Medical Countermeasures

Biodefense Research, Development and Procurement Issues (Non-Funding)
---BIOSECURE Act
---Risky Research Review Act
---Bio COMPETES (Draft)
---Gene Editing
---MCM PRV Program
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---WHO Pandemic Preparedness Accord
---Executive Order on Achieving Efficiency Through State and Local Preparedness
---Executive Order on Withdrawing the United States from the World Health Organization
---HHS Reorganization

Pandemic Preparedness
--- Drug Supply Chain Management
--- Monoclonal Antibody Coverage and Utilization
--- Restrictions on Intellectual Property Rights
--- Supply Chain Issues
--- Temporarily Refundable R&D Credit
--- TRIPS Waiver
--- WHO Pandemic Preparedness Accord
--- House GOP RFI on Supply Chain
--- Medical Countermeasure Priority Review Voucher Reauthorization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Natl Security Council (NSC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
--- Centers for Disease Control and Prevention
--- FDA
--- Health Resources and Services Administration (HRSA)
--- HHS Office of Infectious Disease and HIV/AIDS Policy
--- National Institute of Health
--- BARDA
--- ASPR

FY 2026 Appropriations for Specific Issues
--- Antimicrobial Resistance (General)
--- Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Creating Hope Reauthorization Act
--- Funding for Strategic National Stockpile
--- Implementation of the Inflation Reduction Act (IRA)
--- MCM PRV Reauthorization
--- Reauthorization of PAHPA
--- Vaccine Injury Compensation Program (VICP)
--- Prescription Drug User Fee Act (PDUFA) VII Implementation
--- Funding for Women's Health Research
--- Pandemic Flu
--- Pandemic Preparedness - R&D Funding for Medical Countermeasures

Biodefense Research, Development and Procurement Issues
---Bio COMPETES (Draft)
---Gene Editing
---MCM PRV Program
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Risky Research Review Act
---Tropical Disease Priority Review Voucher (PRV) Program
---HHS Reorganization
---Executive Order on Achieving Efficiency Through State and Local Preparedness

CDC Reform

Pandemic Preparedness
---MCM PRV Reauthorization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Drug Pricing
---Antimicrobial Resistance (General)
--- Vaccines and Infectious Diseases
--- Alternative Funding Programs
--- Pandemic Preparedness - R&D Funding for Medical Countermeasures

340B Drug Discount Program
---Executive Order on Access to Affordable Life-Saving Medications
---Program Implementation & Oversight
--- PROTECT 340B Act
--- SUSTAIN 340B Act

Accelerated Approval

Artificial Intelligence (AI)

Alternative Funding Programs

Biosimilars
---Biosimilar Copay
---BSUFA Negotiations
---Implementation of BSUFA Agreement
---Interchangeability and Pharmacy Substitution
---Reimbursement
---Biosimilars Red Tape Elimination Act

Cell & Gene Therapy
--- H.R.1672 - Maintaining Investments and New Innovation (MINI) Act

Clinical Trial Data in China

Diversity & Inclusion
---Decentralized Clinical Trials

Drug Evaluation and Review
---Promising Pathway Act
---FDA Hiring Flexibility

Drug Importation

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Drug Shortages
---Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
---Supply Chain Integrity and Traceability
---Compounded Medicines

Drug Patenting
---Interagency Patent Coordination and Improvement Act
---Prescription Pricing for the People Act
---Preserve Access to Affordable Generics and Biosimilars Act
---Stop STALLING Act
---Restrictions on Intellectual Property Rights
---Patent Thickets

Drug Pricing
---H.R.946: ORPHAN Cures Act
--- H.R. 1492 Ensuring Pathways to Innovative Cures (EPIC) Act
--- H.R.1672 Maintaining Investments and New Innovation (MINI) Act
---Interagency Patent Coordination and Improvement Act of 2025
---PBM Reform
---Prescription Pricing for the People Act
---Pharmacy Benefit Manager Transparency Act
---Preserve Access to Affordable Generics and Biosimilars Act
---Stop STALLING Act
---CMMI Authority
---Implementation of the Inflation Reduction Act (IRA)
---Patient Cost-Sharing and Implementation
---Strengthening Innovation in Medicare and Medicaid Act
---Most Favored Nation

Foreign Drug Data Protection Laws
---Bio COMPETES (Draft)
---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern
---House GOP RFI on Supply Chain
---Regulatory Harmonization

Medicaid
---Pharmacy Benefit Manager Transparency Act
---Alternative Payment Arrangements for Gene Therapies
---Average Manufacturer Price Calculations
---Coverage of Accelerated Approval Products
---Drug Benefit Design
---Encouraging Innovation Benefit Design to Lower Costs for Seniors Act
---Medicaid Drug Rebate Program
---Most Favored Nation
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

National Defense
---National Defense Authorization Act of 2025

Opioid Crisis
---SUPPORT Act
---Non-Opioid Analgesics
---Transparency
---Coverage and Reimbursement

Orphan Drug Issues
---H.R.946: ORPHAN Cures Act
---S. 946 ORPHAN Cures Act
---Give Kids A Chance Act
---Pediatric Priority Review Voucher Program Reauthorization
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Orphan Drug Tax Credit

Pandemic Preparedness
--- Drug Supply Chain Management
--- House GOP RFI on Supply Chain
--- Monoclonal Antibody Coverage and Utilization
--- Restrictions on Intellectual Property Rights
--- Supply Chain Issues
--- WHO Pandemic Preparedness Accord
--- Medical Countermeasure Priority Review Voucher Reauthorization

Precision Medicine Initiative

Reimbursement and Coverage of Innovative Products
--- HR 3375 Fair Prescription Drug Prices for Americans Act
--- HR 3493 Global Fairness in Drug Pricing Act
--- S.1587 Fair Prescription Drug Prices for Americans Act
--- S.1818 Prescription Drug Price Relief Act
---HELP Copays Act
---Administration Rebate Rule
---CMMI Authority
---In-Home Administration of Part B Drugs
---Medicare Part B Physician-Administered Products
---National Coverage Determination
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications

Vaccines and Infectious Diseases
---Adult Immunization
--- Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act
---Countermeasures Injury Compensation Program
---Vaccine Injury Compensation Program
---Maternal Immunization
---MCM Manufacturing & Capacity
---MCM PRV Reauthorization
---Monoclonal Antibody Coverage and Utilization
---National Coverage Determination
---Vaccine Safety and Quality
---Vaccine Safety Net and Vaccine Infrastructure
---Value of Vaccines and Vaccine Confidence

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), White House Office, Treasury - Dept of, U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Capital Formation Incentives
---American Innovation Act
---Putting Investors First Act
---Fair Investment Opportunities for Professional Experts Act
---Accredited Investor Definition Review Act
---Helping Startups Continue to Grow Act
---American Innovation and R&D Competitiveness Act
---Small Entity Update Act
---Expanding Access to Capital Act
---American Innovation and Jobs Act
---Implementation of the Inflation Reduction Act (IRA)

Capital Market Enhancements
---Accredited Investor Definition
---Amended Definition of Smaller Reporting Company
---Public Float Threshold Update

Small Business Innovation Research (SBIR) Program
---Reauthorization of SBIR and STTR
---Implementation of the SBIR and STTR Extension Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Commerce - Dept of (DOC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
--- Vaccines and Infectious Diseases
--- VICP

Biofuels and SAF
---Incentives for Sustainable Aviation Fuels
---Sustainable Aviation Fuels Tax Credit
---Carbo Capture Utilization Parity

Capital Formation Incentives
---American Innovation Act
---Helping Startups Continue to Grow Act
---American Innovation and R&D Competitiveness Act
---Small Entity Update Act
---Expanding Access to Capital Act
---Equal Opportunity for All Investors Act
---American Innovation and Jobs Act
---Implementation of the Inflation Reduction Act (IRA)
---Orphan Drug Tax Credit (Camerons Law)

Pandemic Preparedness

Renewable Chemicals/Bio-based Products
---Climate Issues & impact on the agriculture and food sectors

Research & Development Tax Credit Reforms
---American Innovation and R&D Competitiveness Act
---American Innovation and Jobs Act
---Expensing of R&D Expenditures
---R&D Payroll Credit
--- Net Operating Loss Legislation
--- HR 1 One Big Beautiful Bill Act

Vaccines and Infectious Disease
---Let Injured Americans Be Legally Empowered (LIABLE) Act
---Countermeasure Injury Compensation Fund Amendment Act
---VICP
---Vaccine Injury Compensation Modernization Act
---Vaccine Access Improvement Act
---VICP CICP (Discussion Draft)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

CFIUS and Foreign Investment

Drug Importation
---Counterfeit Drug Monitoring

Drug Pricing
---Reference Pricing in Drug Reimbursement
---H.R.946: ORPHAN Cures Act
---H.R. 1492 Ensuring Pathways to Innovative Cures (EPIC) Act
--- H.R.1672 Maintaining Investments and New Innovation (MINI) Act
---Most Favored Nation
---Tariffs

Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---International Consistency of Regulation for Gene Edited Products
---Korea Biotechnology Regulations

Foreign Drug Data Protection Laws
---BIOSECURE Act
---Protecting Americans Data from Foreign Adversaries Act
---A bill to prohibit contracting with certain biotechnology providers, and for other purposes.
---Bio COMPETES (Draft)
---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern
---House GOP RFI on Supply Chain

Genetically Engineered (GE) Animals
---International Consistency of Regulation for Gene Edited Products

Genetically Engineered (GE) Plants
---International Consistency of Regulation for Gene Edited Products

Intellectual Property International Enforcement
---China

Synthetic Biotech

Tariffs

Trade Relations
--- United Nations - General
--- Section 232
--- US-China Ag-Biotech Provisions
--- US China IP Provisions
--- World Trade Organization (WTO) - General
---Food and Ag Organization (FAO)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), State - Dept of (DOS), Treasury - Dept of

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes